Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Tamara K Moyo, MD PhD, Andrew Sochacki, MD, Gregory D Ayers, MS, Michael T. Byrne, DO, Stephen A. Strickland, Sanjay R. Mohan, MD, Jill Harrison, Lynne D Berry, Channing V Dudley, Rachel Severs, Laura Dugger, Hari P. Miskin, MS, Amy Cavers, Peter Sportelli, Laura C Michaelis, MD, Ruben A. Mesa, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 1125.

https://doi.org/10.1182/blood.V128.22.1125.1125

Published: 2016

Journal Articles

Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202

Kamira Karen Maharaj, BS, John J. Powers, B.S., Mibel Pabon-Saldana, Renee Fonseca, Alex Achille, BS, Susan Deng, BS, Hari P. Miskin, MS, Dave Maryanski, Eva Sahakian, PhD, Javier Pinilla-Ibarz, MD PhD

Blood (2016) 128 (22): 3236.

https://doi.org/10.1182/blood.V128.22.3236.3236

Published: 2016

Journal Articles

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Matthew S. Davids, Haesook T. Kim, PhD, Alyssa Nicotra, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Hari P. Miskin, MS, Peter Sportelli, Asad Bashey, MD PhD, Laura Stampleman, MD, Jens Rueter, MD, Adam Boruchov, MD, Jon Arnason, MD, Caron A. Jacobson, MD, David C. Fisher, MD, Jennifer R. Brown

Blood (2016) 128 (22): 641.

https://doi.org/10.1182/blood.V128.22.641.641

Published: 2016

Journal Articles

A Phase I Trial of TGR-1202, a Next Generation Once-Daily PI3Kδ Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma

Radhakrishnan Ramchandren, MD, Carolyn M. Mulroney, MD, Manish R. Patel, MD, Peter Sportelli, Hari P. Miskin, MS, Robert W Chen, MD

Blood (2016) 128 (22): 4146.

https://doi.org/10.1182/blood.V128.22.4146.4146

Published: 2016

Journal Articles

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Matthew Lunning, DO, Philip J Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Susan Blumel, RN, BSN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Julie M Vose, MD

Blood (2016) 128 (22): 4197.

https://doi.org/10.1182/blood.V128.22.4197.4197

Published: 2016

Journal Articles

A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia

Daruka Mahadevan, MD PhD, Emily K. Pauli, BMBS, PharmD, Kathy Cutter, RN, BSN, Lee Ann Dietz, RN, Peter Sportelli, Hari P. Miskin, MS, Marshall T. Schreeder, MD

Blood (2015) 126 (23): 2942.

https://doi.org/10.1182/blood.V126.23.2942.2942

Published: 2015

Journal Articles

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

Owen A. O'Connor, MD, Ian W. Flinn, MD PhD, Manish R. Patel, MD, Timothy S. Fenske, MD, Changchun Deng, MD PhD, Danielle M. Brander, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John G Kuhn, Pharm.D., Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Howard A. Burris, III, MD

Blood (2015) 126 (23): 4154.

https://doi.org/10.1182/blood.V126.23.4154.4154

Published: 2015

Journal Articles

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

Matthew A. Lunning, DO, Julie Vose, Nathan Fowler, MD, Loretta Nastoupil, MD, Jan A. Burger, MD PhD, William Wierda, MD PhD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher Flowers, MD, Jonathon B. Cohen, MD, Susan Blumel, RN, BSN, Myra Miguel, RN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Ryan Handy, BS, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Susan O'Brien, MD

Blood (2015) 126 (23): 1538.

https://doi.org/10.1182/blood.V126.23.1538.1538

Published: 2015

Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

Kathryn Kolibaba, MD, John M. Burke, MD, Heather D. Brooks, MD BS, BA, Daruka Mahadevan, MD PhD, Jason Melear, MD, Charles M. Farber, MD PhD, Suzanne R. Fanning, DO, Marshall T. Schreeder, MD, Ralph V. Boccia, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Jeff P. Sharman, MD

Blood (2015) 126 (23): 3980.

https://doi.org/10.1182/blood.V126.23.3980.3980

Published: 2015

Journal Articles

Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma

Matthew A. Lunning, DO, Julie M. Vose, MD MBA, Marshall T. Schreeder, MD, Nathan Fowler, MD, Loretta J. Nastoupil, MD, Tanya Siddiqi, MD, Susan Blumel, RN, BSN, Emily K. Pauli, BMBS, PharmD, Kathy Cutter, RN, BSN, Warner Tse, RN, Hari P. Miskin, MS, Peter Sportelli, Michael S. Weiss, Swaroop Vakkalanka, PhD, Srikant Viswanadha, PhD, Susan O'Brien, MD

Blood (2014) 124 (21): 801.

https://doi.org/10.1182/blood.V124.21.801.801

Published: 2014

Journal Articles

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

Changchun Deng, MD PhD, Mark Lipstein, B.S., Xavier Jirau Serrano, Michael Mangone, PhD, Luigi Scotto, PhD, Owen A O'Connor, MD, PhD, Peter Sportelli, Hari P. Miskin, MS, Srikant Viswanadha, PhD

Blood (2014) 124 (21): 1770.

https://doi.org/10.1182/blood.V124.21.1770.1770

Published: 2014

Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

Jeff P. Sharman, MD, Charles M. Farber, MD PhD, Daruka Mahadevan, MD PhD, Marshall T. Schreeder, MD, Heather D. Brooks, MD, Kathryn S. Kolibaba, MD, Suzanne R. Fanning, DO, Leonard M. Klein, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Daniel R. Greenwald, MD

Blood (2014) 124 (21): 4679.

https://doi.org/10.1182/blood.V124.21.4679.4679

Published: 2014

Journal Articles

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Howard A. Burris, MD, Manish R. Patel, MD, Danielle M. Brander, MD, Owen A. O'Connor, MD PhD, Changchun Deng, MD PhD, Timothy S. Fenske, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John Kuhn, PharmD, Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Ian Flinn

Blood (2014) 124 (21): 1984.

https://doi.org/10.1182/blood.V124.21.1984.1984

Published: 2014

Journal Articles

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells

Changchun Deng, M.D, PH.D., Christine McIntosh, Richard Rodriguez, B.S., Peter Sportelli, Hari P. Miskin, MS, Swaroop Vakkalanka, PhD, Srikant Viswanadha, Ph.D., Mark Lipstein, B.S., Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 4421.

https://doi.org/10.1182/blood.V122.21.4421.4421

Published: 2013

NARROW

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

A Phase I Trial of TGR-1202, a Next Generation Once-Daily PI3Kδ Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only